ClinicalTrials.gg
CompletedNCT03761017Updated Mar 6, 2025

MGD019 DART® Protein in Unresectable/Metastatic Cancer

A Phase 1 interventional study of Lorigerlimab in Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic and Cutaneous Melanoma, sponsored by MacroGenics. Completed at 39 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by MacroGenics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
162
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Melanoma by MacroGenics — 1 open to participants now, 1 under way, none of them phase 3. Melanoma · MacroGenics.

Enrollment
4th of 10
162 · median 145
Started
2018
with 1 other
Phase 1
8 of 10
1 open now
Registered
7th of 10
by date

Among the 10 studies in Melanoma by MacroGenics, this one is the 4th largest by enrollment, is one of 2 that started in 2018, is one of 8 in phase 1, and was the 7th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 10 studies in Melanoma by MacroGenics is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Melanoma by MacroGenics, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.

This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/administered dose (MTD/MAD) of MGD019. Dose escalation will occur in a 3+3+3 design in patients with advanced solid tumors of any histology. Once the MTD/MAD is determined, a Cohort Expansion Phase will be enrolled to further characterize safety and initial anti-tumor activity in patients with specific tumor types anticipated to be sensitive to dual checkpoint blockade.

03

Conditions studied

  • Squamous Cell Non Small Cell Lung Cancer
  • Prostate Cancer Metastatic
  • Cutaneous Melanoma
  • Colorectal Cancer
  • Advanced Cancer
  • Solid Tumor, Adult
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dose escalation: Patients with proven, unresectable, locally advanced or solid tumors for whom no approved therapy with demonstrated clinical benefit is available or patients who are intolerant to standard therapy.
  • Cohort Expansion Phase:
  • -naïve squamous cell NSCLC, including:

    1. Patients that have progressed during or following treatment with platinum-based chemotherapy for advanced disease. Patients harboring an activating epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement must have progressed following at least one available EGFR or ALK targeted therapy. ROS1 rearrangement or BRAF mutation must have progressed following at least 1 available EGFR (including osimertinib for EGFR T790M-mutated NSCLC), ALK, ROS1 or BRAF targeted therapy, respectively
    2. Patients that have progressed during or following treatment with platinum-based chemotherapy for advanced disease and patients with previously untreated squamous cell NSCLC without activating mutations for whom checkpoint inhibitor therapy is not approved or available.
  • Advanced non-microsatellite instability-high colorectal cancer (CRC) with recurrence, progression, or intolerance to standard therapy consisting of at least 2 prior standard regimens. CRC harboring an activating EGFR mutation must have progressed during or following at least one available EGFR targeted therapy. Patients who are inappropriate candidates for or have refused treatment with these regimens are also eligible. Patients should have received no more than 4 .
  • Checkpoint inhibitor-naïve mCRPC that has progressed during or following no more than 2 prior lines of an androgen receptor antagonist or androgen synthesis inhibitor (e.g., enzalutamide or abiraterone, respectively), if approved and available, with a PSA value of at least 2 ng/mL and meeting at least one of the following:
  • Progression in ( v1.1).
  • Appearance of 2 or more new bone lesions according to Prostate Cancer Working Group 2 (PCWG-2).
  • Rising PSA defined as at least two sequential rises in PSA.
  • Eligible patients may have received prior chemotherapy (i.e. docetaxel), and patients with known homologous recombination (HRR) pathway gene alterations must have received the applicable approved therapy (e.g. olaparib).
  • Cutaneous melanoma that has progressed during or following systemic treatment for unresectable, locally advanced, or metastatic disease. Patients will have received PD-(L)1 and/or CTLA-4 pathway inhibitors where available and indicated.
  • (ECOG) performance status of 0-1
  • ≥ 12 weeks.
  • Measurable disease as per RECIST 1.1 for the purpose of response assessment must either (a) not reside in a field that has been subjected to prior radiotherapy or (b) have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrollment.
  • All patients must have an identified formalin-fixed, paraffin embedded (FFPE) tumor specimen (up to 20 slides or a block) for immunohistochemical evaluation of pharmacodynamic markers of interest. Patients may undergo a fresh tumor during the screening period if a tumor sample is not available. Patients in the mCRPC expansion cohort with bone only disease not amenable to fresh biopsy may be eligible in consultation with the Sponsor.
  • Acceptable laboratory parameters and adequate organ reserve.

Exclusion criteria

Exclusion Criteria:

  • In patients who have previously received an (e.g., anti-PD-L1, anti-PD-1, anti-CTLA-4), toxicities related to the checkpoint inhibitor must have resolved to ≤ Grade 1 or baseline. Patients with well controlled immune endocrinopathies secondary to prior checkpoint therapy are eligible.
  • Patients with symptomatic . Patients with history of prior CNS metastasis must have been treated, must be asymptomatic, and must not have concurrent treatment for the CNS disease, progression of CNS metastases on magnetic resonance imaging (MRI) or computed tomography (CT) for at least 14 days after last day of prior therapy for the CNS metastases, or concurrent or cord compression.
  • Patients who sustained the following Grade 3 immune checkpoint inhibitor related AEs are ineligible: Ocular AE, changes in liver function tests that met the criteria for Hy's law (> 3 × of either or AST with concurrent > 2 × ULN of total and without alternate etiology), neurologic toxicity, colitis, renal toxicity, pneumonitis.
  • Patients who have received prior therapy with a combination of monoclonal antibodies against PD-1/PD-L1 and CTLA-4 will be excluded in the Cohort Expansion (this does not apply to the melanoma expansion cohort).
  • Patients with any history of known or suspected disease with certain exceptions
  • History of prior allogeneic bone marrow, stem-cell, or solid organ transplantation.
  • History of trauma or major surgical procedure within 4 weeks prior to initiation of study drug administration.
  • Systemic antineoplastic therapy, or therapy (for all tumor types) or androgen receptor antagonist/androgen synthesis inhibitor for mCRPC (e.g., enzalutamide or abiraterone, respectively) within the 4 weeks prior to initiation of study drug administration.
  • Treatment with radiation therapy within 2 weeks prior to initiation of study drug administration.
  • Radioligand (e.g., radium-223) within 6 months prior to initiation of study drug administration for mCRPC in the Cohort Expansion Phase.
  • Serum testosterone > 50 ng/dl or > 1.7 nmol/L for mCRPC in the Cohort Expansion Phase.
  • Confirmed or presumed COVID-19/SARS-CoV-2 infection. While SARS-CoV-2 testing is not mandatory for study entry, testing should follow local clinical practice guidelines/standards. Patients with a positive test result for SARS-CoV-2 infection, known asymptomatic infection, or presumed infection are excluded. Patients may be considered eligible after a resolved SARS-CoV-2 infection once he or she remains afebrile for at least 72 hours and after other SARS-CoV-2-related symptoms have fully recovered to baseline for a minimum of 72 hours
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Cohort 1

    0.03 mg/kg administered IV every 3 weeks.

    Biological: Lorigerlimab

  • Experimental
    Cohort 2

    0.1 mg/kg administered IV every 3 weeks.

    Biological: Lorigerlimab

  • Experimental
    Cohort 3

    0.3 mg/kg administered IV every 3 weeks.

    Biological: Lorigerlimab

  • Experimental
    Cohort 4

    1.0 mg/kg administered IV every 3 weeks.

    Biological: Lorigerlimab

  • Experimental
    Cohort 5

    30. mg/kg administered IV every 3 weeks.

    Biological: Lorigerlimab

  • Experimental
    Cohort 6

    6.0 mg/kg administered IV every 3 weeks.

    Biological: Lorigerlimab

  • Experimental
    Cohort 7

    10.0 mg/kg administered IV every 3 weeks.

    Biological: Lorigerlimab

Interventions

  • BiologicalLorigerlimab

    Bispecific DART protein binding PD-1 and CTLA-4

    Also known as: MGD019

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.

    Time frame: 30 days after last dose

Secondary outcomes

  1. Cmax

    Maximum Plasma Concentration of lorigerlimab

    Time frame: up to 108 weeks

  2. Tmax

    Time to reach maximum (peak) plasma concentration of lorigerlimab

    Time frame: up to 108 weeks

  3. AUC

    Area Under the Plasma Concentration versus Time Curve of lorigerlimab

    Time frame: up to 108 weeks

  4. Ctrough

    Trough plasma concentration of lorigerlimab

    Time frame: up to 108 weeks

  5. CL

    Total body clearance of the drug from plasma of lorigerlimab

    Time frame: up to 108 weeks

  6. Vss

    Apparent volume of distribution at steady state of lorigerlimab

    Time frame: up to 108 weeks

  7. t1/2

    Terminal half life of lorigerlimab

    Time frame: up to 108 weeks

  8. Percent of patients with anti-drug antibodies against lorigerlimab

    Immunogenicity

    Time frame: up to 108 weeks

  9. Objective response rate (ORR)

    The number of participants who have a complete response (CR) or partial response (PR) to treatment. Efficacy assessed using conventional Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Time frame: Every 12 weeks, up to 4 years

  10. Duration of Response (DoR)

    DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first

    Time frame: Every 12 weeks until withdrawal of consent, lost to follow up, death, or end of the study, up to 4 years

  11. Progression free survival (PFS)

    PFS is defined as the time from the first dose date to the date of first documented PD or death from any cause, whichever occurs first.

    Time frame: Tumor status assessed every 12 weeks. Survival status is assessed approximately every 12 weeks after the last dose of study treatment until withdrawal of consent, lost to follow up, death, or end of the study, up to 4 years

  12. Overall survival (OS)

    OS is defined as the time from the first dose date to the date of death from any cause.

    Time frame: OS status is assessed approximately every 12 weeks after the last dose of study treatment until withdrawal of consent, lost to follow up, death, or end of the study, up to 4 years

  13. Prostate specific antigen (PSA) response rate in mCRPC

    Percent of patients with 50% or more decline in PSA and confirmed 3 weeks later

    Time frame: Every 3 weeks on treatment, then every 3 months up to 2 years post last treatment

  14. Best PSA percent change in mCRPC

    Best percent change in PSA from baseline

    Time frame: Every 3 weeks on treatment, then every 3 months up to 2 years post last treatment

  15. Duration of PSA response

    Time from PSA response to time of PSA progression

    Time frame: Every 3 weeks on treatment, then every 3 months up to 2 years post last treatment

  16. Radiographic progression-free survival (PFS) in metastatic castration-resistant prostate cancer (mCRPC)

    Time from first dose to first occurrence of radiographic progression, or death

    Time frame: up to 2 years post last treatment

  17. Time to PSA progression in mCRPC

    The time from the first dose of MGD019 to the first documented PSA progression. PSA progression is defined as an increase that is ≥ 25% and ≥ 2 ng/mL the baseline or lowest value observed, and which confirmed by a second value at least 3 weeks later

    Time frame: PSA is assessed every 3 weeks while on treatment, every 3 months for up to 2 years post-treatment

07

Study locations

39 sites
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02215, United States
  • START Midwest
    Grand Rapids, Michigan 49546, United States
  • Oncology Hematology West p.c. dba Nebraska Cancer Specialists
    Grand Island, Nebraska 68803, United States
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • UPMC Hillman Cancer Center
    Camp Hill, Pennsylvania 17011, United States
  • UPMC Hillman Cancer Center
    Carlisle, Pennsylvania 17015, United States
  • UPMC Hillman Cancer Center
    Erie, Pennsylvania 16505, United States
  • UPMC Pinnacle Harrisburg
    Harrisburg, Pennsylvania 17101, United States
  • UPMC Pinnacle - Community Osteopathic Medical Sciences Pavilion (MSP)
    Harrisburg, Pennsylvania 17109, United States
  • UPMC Pinnacle - Ortenzio Cancer Center (OCC)
    Mechanicsburg, Pennsylvania 17050, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 20850, United States
  • UPMC Hillman Cancer Center at UPMC Memorial
    York, Pennsylvania 17408, United States
  • The Sarah Cannon Research Institute / Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Complex Oncology Center - Burgas" EOOD, Department of Medical Oncology
    Burgas, 8000, Bulgaria
  • Multiprofile Hospital for Active Treatment-Uni Hospital
    Panagyurishte, Bulgaria
  • Multiprofile Hospital for Active Treatment "Heart and Brain"" EAD, Clinic of Medical Oncology
    Pleven, Bulgaria
  • Complex Oncology Center - Ruse EOOD
    Ruse, 7002, Bulgaria
  • University Mulitprofile Hospital for Active Treatment "Sv. Ivan Rilski
    Sofia, 1431, Bulgaria
  • University Clinical Centre, Early Clinical Trials Unit
    Gdańsk, 80-214, Poland
  • Pratia MCM Krakow
    Kraków, Poland
  • Europejskie Centrum Zdrowia Otwock
    Otwock, 05-400, Poland
  • Med-Polonia Sp. z.o.o.
    Poznań, 60-693, Poland
  • LUX MED Onkologia Sp. z.o.o.
    Warszawa, 01-748, Poland
  • Narodowy Instytut Onkologii im
    Warszawa, 02-781, Poland
  • Mazovian Onkological Hospital
    Wieliszew, Poland
  • ICO Badalona / Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital Ruber Internacional
    Madrid, 20834, Spain
  • Hospital Universitario La Princesa
    Madrid, 28006, Spain
  • Communal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro
    Dnipro, Ukraine
  • Communal Non-Profit Enterprise "Regional Center of Oncology", Oncosurgical Department of Head and Neck
    Kharkiv, Ukraine
  • Communal Nonprofit Enterprise "Regional Clinical Oncology Center of Kirovohrad Regional Council"
    Kirovohrad, Ukraine
  • Kyiv City Clinical Oncological Centre
    Kyiv, Ukraine
  • National Cancer Institute of Ukraine
    Kyiv, Ukraine
  • Sumy Clinical Oncological Hospital
    Sumy, Ukraine
  • Communal Nonprofit Enterprise "Podilsky Regional Center of Oncology"
    Vinnytsia, Ukraine
08

References and documents

Publications

  • Berezhnoy A, Sumrow BJ, Stahl K, Shah K, Liu D, Li J, Hao SS, De Costa A, Kaul S, Bendell J, Cote GM, Luke JJ, Sanborn RE, Sharma MR, Chen F, Li H, Diedrich G, Bonvini E, Moore PA. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163. doi: 10.1016/j.xcrm.2020.100163. eCollection 2020 Dec 22. PubMed 33377134 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Aug 2024, 68 months.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 68 months is above that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2018
First posted
Dec 3, 2018
StartActual
Dec 12, 2018
Primary completionActual
Aug 29, 2024
CompletionActual
Jan 27, 2025
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03761017
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
Dec 3, 2018
Start date
Dec 12, 2018
Primary completion
Aug 29, 2024
Completion
Jan 27, 2025
Last update
Mar 6, 2025

Study contacts

Denise Casey, MD
study director · MacroGenics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorigerlimab

Start the discussion